Arjun Agarwal

SVP Finance Arjun Agarwal sells 10.0K shares for $846.2K via scheduled 10b5-1 plan at ORKA; retains 101,459 and 61,250 option shares.

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales totaling 9,999 shares for $846.2K on 2026-07-13 under a pre-arranged 10b5-1 trading plan, meaning this is a scheduled, non-discretionary transaction. His non-derivative holdings fell from 25.3K to 15.3K shares, but he retains 101,459 and 61,250 employee stock options, so his overall equity stake remains substantial. The stock trades at $84.56, having gained 21.0% over 30 days and 26.1% over 90 days from lows of $12.84, placing it -13.5% from a 52-week high of $97.78. The company reported $0.00 in revenue and a net loss of $-31.8M in its latest period, underpinning a $5.1B market cap despite unprofitability—a data point investors should weigh against the recent price momentum.

SVP Finance Agarwal sells 9,459 shares at $69.72 avg for $659.5K under 10b5-1 plan at unprofitable biotech

Arjun Agarwal, Senior Vice President Finance at Oruka Therapeutics, executed 3 separate sales totaling 9,459 shares for $659,507.59 at blended average price $69.72 on 2026-06-12. The transaction was conducted under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. His holdings reduced from 26,753 shares to 17,294 shares post-transaction. The company reported $0.00 revenue in its latest quarter with a net loss of $-31,820,000.00, and remains unprofitable. The stock currently trades at $68.86, near the transaction prices but down 24.3% from its 52-week high of $91.00. Prior trades by Agarwal at this same ticker (4 sales on 2026-05-18) lack measurable 30-day and 90-day outcomes.

SVP Agarwal sells 10,290 shares of ORKA for $607.8K in 4 scheduled transactions under 10b5-1 plan

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales on 2026-05-18 totaling 10,290 shares for $607,806.41 at a blended average price of $59.07. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. Post-transaction, Agarwal holds 16,406 shares, down from 26,696 shares, representing a 38.5% reduction in his holdings. The stock trades at $58.34, down 35.9% from its 52-week high of $91.00, and the company posted $0.00 revenue in the latest quarter with a net loss of $31.8M, indicating ongoing unprofitability. The scheduled nature of this filing precludes attribution of timing intent to the insider.